{"table_id": "Tab3", "table_label": "Table 3", "table_caption": "Pre-treatment demographics, headache and migraine frequency, scores on ASC-12, MIDAS, BDI, and temperatures required to elicit moderate intensity pain. Medication overuse refers to participants who were using abortive medications more often than the thresholds defined for medication overuse by the ICHD-3 diagnostic criteria. Concurrent migraine preventive medication refers to the percentage of participants who were using migraine preventive medications in addition to erenumab. There were no differences in these pre-treatment values between participants who became erenumab responders vs. erenumab non-responders except that a larger proportion of participants who became erenumab responders were using concurrent migraine preventive medications. ASC-12\u2009=\u2009Allodynia Symptom Checklist 12; MIDAS\u2009=\u2009Migraine Disability Assessment; BDI\u2009=\u2009Beck Depression Inventory", "n_header_rows": 1, "table_data_file": "table_002.csv"}